<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403948</url>
  </required_header>
  <id_info>
    <org_study_id>1270.2</org_study_id>
    <secondary_id>2010-024456-29</secondary_id>
    <nct_id>NCT01403948</nct_id>
  </id_info>
  <brief_title>BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose is to investigate the maximum tolerated dose (MTD), safety and tolerability,
      pharmacokinetics and efficacy of BI 836826 monotherapy in patients with relapsed or
      refractory non-Hodgkin lymphoma with at least prior treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2011</start_date>
  <completion_date type="Actual">January 3, 2018</completion_date>
  <primary_completion_date type="Actual">November 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events graded according to CTCAE (version 4.0)</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximun tolerated dose (MTD) as defined by Dose limiting toxicity (DLT)</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour size reduction</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure free survival</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Patients with relapsed or refractory NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836826</intervention_name>
    <description>Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion</description>
    <arm_group_label>Patients with relapsed or refractory NHL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin (mature B
             cell lymphoma according to WHO) not considered candidates for intensive anti-lymphoma
             therapy

          2. Patients must have either aggressive NHL and received at least one prior anti-CD20
             containing immunochemotherapy or indolent NHL and received anti-CD20 therapy and at
             least two prior therapies

          3. Measurable disease on computed tomography (CT) scan with involvement of one clearly
             demarcated lesion =2 cm or two or more clearly demarcated lesions of &gt;1.5 cm at
             longest diameter (this criterion applies only for the expansion cohort)

          4. Relapse or progression of disease with an indication for therapy as per investigator`s
             judgement

          5. Life expectancy of =3 months

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

        Exclusion criteria:

          1. Primary central nervous system (CNS) lymphoma or known CNS involvement

          2. Prior history of malignancy other than a mature B cell neoplasm according to WHO
             classification (except basal cell or squamous cell carcinoma of the skin, or carcinoma
             in situ of the uterine cervix or breast treated with curative therapy) unless the
             subject has been free of disease and without treatment for at least 5 years

          3. Last chemotherapy &lt;4 weeks prior to visit 1

          4. Last anti-CD20 therapy (non-radiolabelled) &lt;4 weeks prior to visit 1

          5. Last corticosteroid &lt;2 weeks prior to visit 1 unless the dose is less or equal of 10
             mg/day prednisolone or equivalent

          6. High-dose therapy with stem cell support &lt;6 months prior to visit 1

          7. Radio-immunotherapy &lt;3 months prior to visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INS Paoli-Calmettes</name>
      <address>
        <city>Marseille Cedex 09</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Georg-August-Universität</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

